Oxaliplatin, 5-fluorouracil, and folinic acid (Folfox) in patients with metastatic renal cell carcinoma - Results of a pilot study

被引：11
作者：
Chaouche, M
Pasturaud, AL
Kamioner, D
Grandjean, M
Franiatte, J
Tourani, JM
机构：
[1] Hop Jean Bernard, Dept Oncol, F-86021 Poitiers, France
[2] Pasteur Hosp, Oncol Unit, Brest, France
[3] Laennec Hosp, Oncol Unit, Paris, France
[4] Trappes Hosp, Oncol Unit, Trappes, France
来源：
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2000年 / 23卷 / 03期
关键词：
5-fluorouracil; immunotherapy; oxaliplatin; renal cell carcinoma;
D O I：
10.1097/00000421-200006000-00016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We report the results of a chemotherapy regimen combining oxaliplatin, 5-fluorouracil, and folinic acid in patients with metastatic renal cell carcinoma. The objective of this pilot study was to define the potential efficacy of this second-line combination in patients previously treated with interleukin-2 alone or in combination with interferon alpha. Fourteen patients with metastatic renal cell carcinoma in failure after immunotherapy were included in this trial. During treatment, patients received six chemotherapy courses (Folfox regimen) administered every 2 weeks. Each cycle combined oxaliplatin day (D) D1 and folinic acid plus 5-fluorouracil D1 and D2. At completion of treatment, no objective response was observed and two patients presented stable disease. This chemotherapy schedule in patients with metastatic renal cell carcinoma previously treated with immunotherapy does not seem to be effective.
引用
收藏
页码：288 / 289
页数：2
相关论文
共 50 条
  • [41] An oxaliplatin plus 5-fluorouracil bolus plus folinic acid (BFOL) regimen as first-line treatment in metastatic colorectal cancer patients
    La Verde, Nicla
    Garassino, Marina
    Bareggi, Claudia
    Sburlati, Paola
    Borgonovo, Karen
    Dimaiuta, Mariastella
    Mantica, Cristina
    Perrone, Silvia
    Torri, Valter
    Farina, Gabriella
    TUMORI, 2007, 93 (06) : 557 - 561
  • [42] A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer
    Luo, Hui-Yan
    Xu, Rui-Hua
    Zhang, Li
    Li, Yu-Hong
    Shi, Yan-Xia
    Lin, Tong-Yu
    Han, Bing
    Wang, Feng
    Qiu, Miao-Zhen
    He, You-Jian
    Guan, Zhong-Zhen
    CHEMOTHERAPY, 2008, 54 (03) : 228 - 235
  • [43] Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients
    Romain Coriat
    Olivier Mir
    Anatole Cessot
    Catherine Brezault
    Stanislas Ropert
    Jean-Philippe Durand
    Wulfran Cacheux
    Stanislas Chaussade
    François Goldwasser
    Investigational New Drugs, 2012, 30 : 376 - 381
  • [44] 5-fluorouracil alone versus 5-fluorouracil plus folinic acid in the treatment of colorectal carcinoma: meta-analysis
    Lo Bello, L
    Pistone, G
    Restuccia, S
    Vinci, E
    Mazzoleni, G
    Malaguarnera, M
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2000, 38 (12) : 553 - 562
  • [45] Treatment of Advanced Gastric Carcinoma Patients with Calcium Folinate,a 5-Fluorouracil Bolus and Continous Infusion with 5-Fluorouracil Combined with Oxaliplatin
    Qilian Liang Saihong Chen Dachao Pan Jierong Xie Liangzhen Cai Shujun Li Center of Oncology
    Chinese Journal of Clinical Oncology, 2008, (04) : 273 - 276
  • [46] Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial
    Comella, P
    Massidda, B
    Filippelli, G
    Palmeri, S
    Natale, D
    Farris, A
    De Vita, F
    Buzzi, F
    Tafuto, S
    Maiorino, L
    Mancarella, S
    Leo, S
    Lorusso, V
    De Lucia, L
    Roselli, A
    ANNALS OF ONCOLOGY, 2005, 16 (06) : 878 - 886
  • [47] A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma
    O'Byrne, KJ
    Philip, PA
    Propper, DJ
    Braybrooke, JP
    Saunders, MP
    Bates, NP
    Taylor, MA
    Madigan, D
    Ganesan, TS
    Talbot, DC
    Harris, AL
    ANNALS OF ONCOLOGY, 1999, 10 (08) : 981 - 983
  • [48] Interstitial lung disease in a patient treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) for metastatic colorectal cancer
    Hannan, Liam M.
    Yoong, Jaclyn
    Chong, Geoffrey
    McDonald, Christine F.
    RADIOLOGY AND ONCOLOGY, 2012, 46 (04) : 360 - 362
  • [49] 5-FLUOROURACIL MONOTHERAPY VERSUS FOLINIC ACID AND 5-FLUOROURACIL IN ADVANCED COLORECTAL-CANCER - RESULTS OF A RANDOMIZED TRIAL
    STEINKE, B
    GUNTHER, E
    HIRSCHMANN, W
    SONDERN, W
    KONICZECK, KH
    WANDER, HE
    NATT, F
    WAGNER, T
    HINRICHS, HF
    ROTH, W
    ONKOLOGIE, 1993, 16 (04): : 252 - 259
  • [50] Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients
    Coriat, Romain
    Mir, Olivier
    Cessot, Anatole
    Brezault, Catherine
    Ropert, Stanislas
    Durand, Jean-Philippe
    Cacheux, Wulfran
    Chaussade, Stanislas
    Goldwasser, Francois
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (01) : 376 - 381
12345